In-vitro activity of DR-3355, an optically active isomer of ofloxacin, against bacterial pathogens associated with travellers' diarrhoea

1989 ◽  
Vol 24 (4) ◽  
pp. 547-549 ◽  
Author(s):  
Yoshio Inagaki ◽  
Sankichi Horiuchi ◽  
Tsutomu Une ◽  
Rintaro Nakaya
Keyword(s):  
Bacterial Pathogens ◽  
Optically Active ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Active Isomer

In-vitro activity of cefepime against bacterial pathogens from hospitalized patients

1993 ◽  
Vol 32 (1) ◽  
pp. 164-166 ◽  
Author(s):  
K. P. KLUGMAN ◽  
J. SAUNDERS ◽  
M. KHOOSAL
Keyword(s):  
Bacterial Pathogens ◽  
Hospitalized Patients ◽  
Vitro Activity ◽  
In Vitro Activity

In vitro activity of an ear rinse containing tromethamine, EDTA, and benzyl alcohol on bacterial pathogens from dogs with otitis

2006 ◽  
Vol 67 (6) ◽  
pp. 1040-1044 ◽  
Author(s):  
Lynette K. Cole ◽  
Dao H. Luu ◽  
Paivi J. Rajala-Schultz ◽  
Cheyney Meadows ◽  
Audrey H. Torres
Keyword(s):  
Benzyl Alcohol ◽  
Bacterial Pathogens ◽  
Vitro Activity ◽  
In Vitro Activity

scholarly journals The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens

2018 ◽  
Vol 90 (1) ◽  
pp. 64-66 ◽  
Author(s):  
David B. Huang ◽  
Leonard R. Duncan ◽  
Robert K. Flamm ◽  
Matthew Dryden ◽  
G. Ralph Corey ◽  
...  
Keyword(s):  
Pulmonary Surfactant ◽  
Bacterial Pathogens ◽  
Vitro Activity ◽  
In Vitro Activity

scholarly journals In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S373-S373 ◽  
Author(s):  
Susanne Paukner ◽  
Helio S Sader ◽  
Jennifer M Streit ◽  
Robert K Flamm ◽  
Steven P Gelone
Keyword(s):  
Respiratory Tract ◽  
Bacterial Pathogens ◽  
Bloodstream Infections ◽  
Vitro Activity ◽  
Asia Pacific ◽  
Respiratory Pathogens ◽  
In Vitro Activity ◽  
Tract Infections ◽  
Research Grant

Abstract Background CABP is the number one reason for death by infectious diseases worldwide and emerging resistance complicates its treatment. Lefamulin is the first semi-synthetic pleuromutilin antibiotic for IV and oral use in humans. It is currently in Phase 3 trials for the treatment of CABP in adults. Lefamulin effectively and selectively inhibits bacterial translation by binding to the peptidyl transferase center (PTC) via four H-bonds and other interactions at the A- and P-site resulting in an “induced fit.” This study investigated the activity of lefamulin and comparators against a contemporary set of bacterial pathogens associated with community-acquired respiratory infections collected worldwide. Methods Unique patients’ isolates (n = 2817) were collected globally in US (19.7%), Europe (36.9%), Latin America (5.7%) and Asia-Pacific region (37.6%) (30 countries, 116 sites) from adult and pediatric patients with respiratory tract infection (88.0%), bloodstream infections (5.5%) and other infections (2.4%). Lefamulin and comparators were tested by CLSI broth microdilution and susceptibility was determined using the CLSI (2017) breakpoints. Results LEF was the most potent compound tested, with 99.7% of all S. pneumoniae isolates being inhibited at a concentration of ≤0.25 mg/L (MIC50/90 values of 0.06/0.12 mg/L) and its activity was not affected by resistance to other antibiotic classes. S. pneumoniae isolates were largely susceptible to levofloxacin (99.1%) and ceftriaxone (96.5%), while 34.5%, 23.3% and 16.8% of isolates were resistant to macrolides, tetracycline and clindamycin, respectively. Lefamulin also showed potent activity against H. influenzae (MIC50/90 of 0.5/1 mg/L), including 22.0% of ß-lactamase producing strains, and M. catarrhalis (0.06/0.12 mg/L). Conclusion Lefamulin demonstrated potent in vitro activity against this global collection of contemporary respiratory pathogens and its activity was unchanged regardless of resistance phenotype to the other antibiotic classes including macrolides, ß-lactams, tetracyclines or fluoroquinolones. These data support the continued clinical development of lefamulin for the treatment of respiratory tract infections, including CABP. Disclosures S. Paukner, Nabriva Therapeutics: Employee and Shareholder, Salary; H. S. Sader, Nabriva Therapeutics: Research Contractor, Research grant; J. M. Streit, Nabriva Therapeutics: Research Contractor, Research grant; R. K. Flamm, Nabriva Therapeutics: Research Contractor, Research grant; S. P. Gelone, Nabriva Therapeutics: Employee and Shareholder, Salary

In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany

2020 ◽  
Vol 56 (4) ◽  
pp. 106128
Author(s):  
Michael Kresken ◽  
Miriam Korte-Berwanger ◽  
Sören G. Gatermann ◽  
Yvonne Pfeifer ◽  
Niels Pfennigwerth ◽  
...  
Keyword(s):  
Bacterial Pathogens ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Gram Negative

Abstract 135: In Vitro Activity of Antimicrobial Drugs Against Clinically Relevant Bacterial Pathogens Under Mild Hypothermic Conditions

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Christian Wallmüller ◽  
Herold Birger ◽  
Fritz Sterz ◽  
Athanasios Makristathis ◽  
Michael Ramharter
Keyword(s):  
Confidence Interval ◽  
Therapeutic Hypothermia ◽  
Bacterial Pathogens ◽  
Mild Therapeutic Hypothermia ◽  
Vitro Activity ◽  
Disc Diffusion ◽  
In Vitro Activity ◽  
Broth Microdilution ◽  
Antimicrobial Drugs

Aim: Infections are a common problem in cardiac arrest survivors. Antimicrobial drugs are often administered in routine care during treatment of patients with mild therapeutic hypothermia. Since there is to date no evidence for the pharmacodynamics of antimicrobial drugs under mild therapeutic hypothermia conditions, we investigated the in vitro activity of common antimicrobials against clinically relevant bacterial pathogens. Methods: Activities of antimicrobial drugs against clinically relevant bacterial pathogens were assessed in vitro by disc diffusion and broth microdilution assays at normothermic (37°C) and hypothermic (32°C) conditions. Results: 73 bacterial isolates were tested in disc diffusion and 15 in broth microdilution assays. Mean differences in zone diameters and minimal inhibitory concentration ratios were 0.6 mm (95% confidence interval: 0.3-0.9 mm) and 0.98; (95% confidence interval: 0.95 - 1.02), respectively, meeting predefined criteria for equivalence of in vitro antimicrobial activity. Conclusion: The presented data provide reassuring evidence that the intrinsic activity of antimicrobials seems to be unaltered in mild therapeutic hypothermia. However, further studies evaluating the pharmacokinetics including target site concentrations of the respective drugs and in vivo pharmacodynamics are necessary to complement our understanding of the appropriate use of antimicrobials in mild therapeutic hypothermia

Sign in / Sign up

Export Citation Format

Share Document